News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan-Kettering Cancer Center For Novel Vaccine Platform



1/8/2009 8:39:18 AM

NEW YORK--(BUSINESS WIRE)--Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky. Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES